TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06594393: A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study

Sponsor: Xinnate AB · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 32 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$1,626,800

Rescue Site Savings

+$1,062,400

Unlock Full NCT06594393 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06594393 Rescue Dossier →